Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

Sinha, Shubhadeep; Ghosh, Biswadip; Bandyopadhyay, Syamasis; Fatima, Firdaus; Bandi, Vamsi Krishna; Thakur, Pankaj; Reddy, Bala; Chary, Sreenivasa; Talluri, Leela; Gupta, Ajay; Kale, Amit Ramchandra; Gupta, Anil Kumar; P, Ashok Kumar; Reddy, Diwakar; Mohammed, Younus; Shekar, Soma; T, Sudheer; Goni, Vijay G.; Sharma, Vishnu; Yeligod, Vishwanath

doi:10.1186/s41927-020-00124-9

BMC Rheumatology

Article metrics
Last updated: Fri, 19 Apr 2024 14:52:06 Z

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

Access & Citations

2927

Article Accesses
5

Web of Science
5

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 2520-1026

Contact us

Submission enquiries: bmcrheumatology@biomedcentral.com
General enquiries: ORSupport@springernature.com